Shuozhou Shuocheng Jiayin Trading Co., Ltd. – Trademark Portfolio

Entity Type: 99

Shuozhou Shuocheng Jiayin Trading Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include GARFILY. The owner is based in Shuozhou, Shanxi.

Sub-district, Shuo Cheng District,

Store 23, Building 25, Lan Cao Yuan

Shuozhou, Shanxi 036000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

GARFILY
GARFILY
Registered 2024

Trademark Classifications

Shuozhou Shuocheng Jiayin Trading Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Shuozhou Shuocheng Jiayin Trading Co., Ltd. have?

Shuozhou Shuocheng Jiayin Trading Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shuozhou Shuocheng Jiayin Trading Co., Ltd. file in?

Shuozhou Shuocheng Jiayin Trading Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Shuozhou Shuocheng Jiayin Trading Co., Ltd.'s most well-known trademarks?

Shuozhou Shuocheng Jiayin Trading Co., Ltd.'s registered trademark portfolio includes well-known marks such as GARFILY. These are among 1 currently registered trademark in the portfolio.

What is Shuozhou Shuocheng Jiayin Trading Co., Ltd.'s trademark registration success rate?

Shuozhou Shuocheng Jiayin Trading Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.